NCT05569356View on ClinicalTrials.gov

Diagnostic Contribution, Prognosis and Physiopathological Aspects in Arrhythmogenic Cardiomyopathy. (ACORE)

Not yet recruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

October 20, 2022

Primary Completion Date

October 20, 2032

Study Completion Date

October 20, 2032

Conditions
Arrhythmogenic Cardiomyopathy
Interventions
BIOLOGICAL

Prospective

-Additional blood samples -Myocarditis biopsy sample (routine care) -Additional pericardial fluid sample (routine care)

OTHER

Retrospective

None (only data collection)

Trial Locations (1)

75013

Institut de Cardiologie de la Pitié-Salpêtrière, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT05569356 - Diagnostic Contribution, Prognosis and Physiopathological Aspects in Arrhythmogenic Cardiomyopathy. (ACORE) | Biotech Hunter | Biotech Hunter